Q2 2026 Iovance Biotherapeutics Inc Earnings Call Transcript
Key Points
- Record Q2 2026 revenue of $99.3 million, driven by strong Amtagvi demand and exceeding guidance.
- Gross margin reached an all-time high of 56%, up from 41% in Q1, with expectations for further expansion.
- R&D expenses decreased for the fourth consecutive quarter, demonstrating operational discipline and efficiency gains.
- FDA granted Fast Track designation for lifileucel in two advanced soft tissue sarcomas, validating the program's potential.
- Early Phase 2 data in metastatic serous endometrial cancer showed a 40% confirmed objective response rate and 100% disease control rate.
- Expanding commercial footprint with over 95 ATCs, including a growing community presence, and strong payer coverage (75% private payers).
- Cash position of $304 million is expected to fund operations into the second half of 2028, supporting long-term growth.
- Proleukin revenue declined slightly in Q2 due to timing of wholesaler inventory stocking, though expected to stabilize.
- Full-year 2026 revenue guidance was not updated, with management only committing to a review during Q3, creating uncertainty.
- LUN-202 trial enrollment is nearly complete but not finished, and top-line data will not be available until Q4, with potential delays.
- Competitive threats from emerging therapies (e.g., Replimune's oncolytic virus) and other TIL developers could impact market share.
- International expansion is still in early stages, with approvals pending in the UK and Switzerland and EU resubmission ongoing.
- The company faces challenges in penetrating larger community networks, which may limit patient access and growth.
- Despite progress, the company is not yet profitable, and achieving profitability depends on continued revenue growth and cost management.
Thank you. Welcome to the Iovance Biotherapeutics second quarter 2026 conference call. My name is Daniel, and I will be your operator for today's call. (Operator Instructions) Please note that this conference call is being recorded. I will now turn the call over to Sarah Pellegrino, Senior Vice President, Investor Relations and Corporate Communications at Iovance.
Sarah, you may begin.
Thank you, operator. Good morning, and welcome to the Iovance webcast to discuss our second quarter of 2026 results, business achievements, and corporate updates. This morning we issued a press release that is available on our corporate website at iovance.com. This conference call will include forward-looking statements regarding Iovance's goals, business focus, business plans and transactions, revenue and revenue guidance, commercial activities, clinical trials and results, regulatory approvals, submissions, feedback and guidance, plans and strategies,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
